NCT06959979View on ClinicalTrials.gov

Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Medulloblastoma, Childhood
Interventions
DRUG

CDK4/6 Inhibitor (Palbociclib, Ribociclib, Abemaciclib)

Evaluation of the response to CDK4/6 inhibitors (Palbociclib, Ribociclib, Abemaciclib) on selected Medulloblastoma (MB) patient-derived organoids (PDOs).

Trial Locations (1)

00151

RECRUITING

Fondazione Policlinico Gemelli Irccs, Roma

All Listed Sponsors
collaborator

Università degli studi di Roma Tor Vergata

UNKNOWN

collaborator

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello

OTHER

collaborator

Università degli Studi di Enna Kore

UNKNOWN

lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER